에이비엘바이오

298380KOSDAQ

40.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 21.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

ABL Bio focuses on a growth-oriented business model through technology licensing (License-out) and joint development based on its dual-antibody platform 'Grabody™'. The company addresses unmet medical needs with global technology transfer cases in areas such as ADCs and immuno-oncology therapies. Its U.S. subsidiary, NEOK Bio, manages ADC clinical trials, and cash inflows from milestone achievements in licensing agreements enhance financial stability.

Number of Employees

108people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

15.86Industry Average 1.200.0Point

13.2x industry avg (risky)

ROE

-23.38Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.47Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲44.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1068.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 44,400Won52-week high 245,50052-week low 39,350

1-month return0.0Point

1m -21.83% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-16